Top

American Journal of Clinical Dermatology

Published in:

01-02-2012 | Adis Drug Clinical Q&A

Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma

Authors: Katherine A. Lyseng-Williamson, Lily P. Yang

Published in: American Journal of Clinical Dermatology | Issue 1/2012

Abstract

Intravenous romidepsin (Istodax®), a histone deacetylase inhibitor, is indicated in the US for the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least one prior systemic therapy. In two noncomparative trials in adults with relapsed, refractory, and/or advanced CTCL, romidepsin was associated with an overall response (i.e. complete or partial response) rate of 34%and 35%, and a complete response rate of 6% (in both trials). Romidepsin had an acceptable tolerability profile, with the most common grade 3 or 4 adverse events considered at least possibly related to romidepsin being hematologic or asthenic in nature.

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas (version 4.2011). Fort Washington (PA): National Comprehensive Cancer Network, Inc., 2011 Aug 24

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975-2008. Bethesda (MD): National Cancer Institute, 2011 Apr 15

Whittaker SJ, Marsken JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003 Dec; 149 (6): 1095–107PubMedCrossRef

Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007 Sep 15; 110 (6): 1713–22

Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70 (3): 273–86PubMedCrossRef

Rahman F, Robey RW, Bates SE, et al. Histone deacetylase inhibitors in oncology. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2011: 442–58

Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009 Nov 10; 27 (32): 5459–68

Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009 Jun 15; 15 (12): 3918–26

Istodax® (romidepsin) for injection: US prescribing information. Summit (NJ): Celgene Corporation, 2011 Jun

10.

Rasheed W, Bishton M, Johnstone RW, et al. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008 Mar; 8 (3): 413–3PubMedCrossRef

11.

Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 Sep; 5 (9): 769–84PubMedCrossRef

12.

Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007 May; 8 (4): 383–93

13.

Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010 Mar; 6 (3): 238–43

14.

Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010 Oct 10; 28 (29): 4485–91

15.

Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 Nov 10; 27 (32): 5410–7

16.

Kim E, Rook A, Kim Y, et al. Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL) [abstract no. 8047]. J Clin Oncol 2010 May 20; 28 (15 Suppl.)

17.

Whittaker S, Kim EJ, Prince M, et al. Characterization of cyclic hematologic changes observed in patients with cutaneous T-cell lymphoma (CTCL) receiving romidepsin, a novel histone deacetylase (HDAC) inhibitor [abstract no. 3701]. Blood 2009 Nov 20; 114 (22)

18.

Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin [abstract no. e19533]. J Clin Oncol 2009 May 20; 27 (15 Suppl.)

19.

Yang LPH. Romidepsin in the treatment of T-cell lymphoma. Drugs 2011; 71 (11): 1469–80PubMedCrossRef

Title: Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma
Authors: Katherine A. Lyseng-Williamson
Lily P. Yang
Publication date: 01-02-2012
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 1/2012
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.2165/11208520-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV Cohort

Erythroid Disturbances Before and After Treatment of Portuguese Psoriasis Vulgaris Patients

Body Piercing

Metformin-Induced Leukocytoclastic Vasculitis

KIT and BRAF Mutational Status in a Patient with a Synchronous Lentigo Maligna Melanoma and a Gastrointestinal Stromal Tumor

Long-Term Treatment of Severe SAPHO Syndrome with Adalimumab